Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ORAI1 | Q96D31 | 3/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | TRPC3 | Q13507 | 3/20 | 0.56 |
| ▸ | TRPC1 | P48995 | 1/20 | 0.56 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.56 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | CRACR2A | Q9BSW2 | 3/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.42 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3281677 | 0.93 | ORAI1 (0.66) | ORAI1MAPTTP53TRPC3TRPC1 | |
| SCHEMBL7323117 | 0.90 | ORAI1 (0.68) | ORAI1MAPTTP53TRPC3TRPC1 | |
| SCHEMBL7319733 | 0.87 | MAPT (0.71) | ORAI1MAPTTP53TRPC3TRPC1 | |
| SCHEMBL3282201 | 0.84 | ORAI1 (0.73) | ORAI1MAPTTP53TRPC3TRPC1 | |
| SCHEMBL7326193 | 0.84 | ORAI1 (0.73) | ORAI1MAPTTP53TRPC3TRPC1 | |
| SCHEMBL7320744 | 0.83 | ORAI1 (0.74) | ORAI1MAPTTP53TRPC3TRPC1 | |
| SCHEMBL3277598 | 0.83 | ORAI1 (0.52) | ORAI1MAPTTP53TRPC3TRPC1 | |
| SCHEMBL3277387 | 0.82 | ORAI1 (0.73) | ORAI1MAPTTP53TRPC3TRPC1 | |
| SCHEMBL7318812 | 0.80 | ORAI1 (0.67) | ORAI1MAPTTP53TRPC3TRPC1 | |
| SCHEMBL5208645 | 0.80 | ORAI1 (1.00) | ORAI1MAPTTP53TRPC3TRPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700655-B2 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20060122243-A1 | Antiallergic | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| US-20060111409-A1 | Medicament for treatment of diabetes | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-25 | — | — | US | disclosed |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20060019958-A1 | Immunity-related protein kinase inhibitors | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512396-A1 | INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019958-A1 | Immunity-related protein kinase inhibitors | MAP3K1, MAP3K7, MAP3K8 | ORAI1 3947/4885MAPT 2937/4885TP53 1193/4885 |
| US-20060111409-A1 | Medicament for treatment of diabetes | XDH, SLC5A1, SLC5A2 | ORAI1 4425/4885MAPT 3517/4885TP53 2579/4885 |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | NAT1, EPX, HRH2 | ORAI1 917/4885MAPT 2536/4885TP53 1951/4885 |
| US-20060122243-A1 | Antiallergic | EPX, NAT1, HNMT | ORAI1 989/4885MAPT 2797/4885TP53 2084/4885 |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | NFATC1, AP1G1, ATF1 | ORAI1 376/4885MAPT 3490/4885TP53 1196/4885 |
| US-20070185110-A1 | Antiallergic agents | NAT1, EPX, AHR | ORAI1 1018/4885MAPT 2469/4885TP53 1879/4885 |
| US-20070185059-A1 | Antiallergic agents | NAT1, EPX, AHR | ORAI1 1034/4885MAPT 2415/4885TP53 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.